Percutaneous ultrasound-guided chemical parathyroid ablation for treatment of primary hyperparathyroidism in dogs.
OBJECTIVE
To evaluate the efficacy, feasibility, and safety of ultrasound-guided chemical ablation of parathyroid masses in dogs with primary hyperparathyroidism.


METHODS
Prospective clinical trial.


METHODS
8 dogs.


METHODS
In all dogs, a solitary parathyroid mass was evident ultrasonographically. Dogs were anesthetized with propofol, and a 27-gauge needle was directed into the parathyroid mass under ultrasound guidance. Ethanol (96%) was injected into the mass until there was evidence of diffusion of fluid throughout the mass. Serum total calcium, ionized calcium, phosphorus, and parathyroid hormone (PTH) concentrations were monitored daily for 5 to 7 days after the ablation procedure and again 1, 3, and 6 months after the procedure. Dogs were also monitored for adverse effects. Follow-up ultrasonography was performed 5 days and 1 month after the ablation procedure.


RESULTS
One injection was required in 7 dogs, and 2 injections were required in 1. Serum total and ionized calcium concentrations were within reference ranges within 24 hours after treatment in 7 dogs and within 5 days in 1 dog. Serum PTH concentration decreased and serum phosphorus concentration increased within 24 hours after treatment in all 8 dogs. Transient hypocalcemia developed in 4 dogs during the first 5 days after treatment, but only 1 dog required treatment for hypocalcemic tetany. Hypercalcemia recurred in 1 dog 1 month after the procedure and surgical removal of the parathyroid mass was required. Other adverse effects were not reported.


CONCLUSIONS
Ultrasound-guided chemical ablation of parathyroid masses is a safe and effective alternative to surgery for dogs with primary hyperparathyroidism.
Long
C D
CD
Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, USA.
Goldstein
R E
RE
Hornof
W J
WJ
Feldman
E C
EC
Nyland
T G
TG
D000236:Adenoma / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000662:veterinary*; D000818:Animals; D002118:Calcium / Q000097:blood; D004283:Dog Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D004285:Dogs; D000431:Ethanol / Q000008:administration & dosage / Q000627:therapeutic use*; D006961:Hyperparathyroidism / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary*; D015552:Injections, Intralesional / Q000662:veterinary; D010281:Parathyroid Hormone / Q000097:blood; D010282:Parathyroid Neoplasms / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000662:veterinary*; D010758:Phosphorus / Q000097:blood; D012997:Solvents / Q000008:administration & dosage / Q000627:therapeutic use*; D014463:Ultrasonography
D010281:Parathyroid Hormone; D012997:Solvents; D010758:Phosphorus; D000431:Ethanol; D002118:Calcium